Loading...
BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability
Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of CML-CP. Unfortunately, 25% of TKI-naive patients and 50–90% of TKI-responding patients carry CML clones expressing TKI resistant BCR-ABL1 kinase mutants. We reported that CML-CP leukemia stem and progenitor cell populations accumulate...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3598941/ https://ncbi.nlm.nih.gov/pubmed/23047475 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.294 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|